CDK4/6i in HR+HER2- breast cancer
Podcast 2021026
Questions:
- The best hormonal partner: evidence on fulvestrant, letrozole or anastrozole.
- Possibility to use CDK4/6i+AI in mBC in patients progressing during or after completion of adjuvant AI treatment.
- Ways of overcoming haematologic toxicities (neutropenia, leucopenia).
- Any evidence on choosing between three drugs of this class currently available (palbociclib, ribociclib, abemaciclib).
- Possible biomarkers of response and effectiveness.
Expert
/attachment.e-eso.net/48/2020072510123242.jpg)
Breast Center, LMU University Hospital
Munich, Germany
Munich, Germany
07
Oct 2021
